评估巢式 PCR 和外泌体 DNA 直接测序在 NSCL 表皮生长因子受体突变检测中的灵敏度

Q2 Biochemistry, Genetics and Molecular Biology
Mohammad Mehdi Jahani, Parisa Mashayekhi, Mir Davood Omrani, Adnan Khosravi, Dehghanifard Ali, Sanam Azad Manjiri, Mahyar Zahraei, Maryam Mabani, Sharareh Seifi, Babak Salimi, Parsa Rostami
{"title":"评估巢式 PCR 和外泌体 DNA 直接测序在 NSCL 表皮生长因子受体突变检测中的灵敏度","authors":"Mohammad Mehdi Jahani, Parisa Mashayekhi, Mir Davood Omrani, Adnan Khosravi, Dehghanifard Ali, Sanam Azad Manjiri, Mahyar Zahraei, Maryam Mabani, Sharareh Seifi, Babak Salimi, Parsa Rostami","doi":"10.61186/ibj.4289","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Early and minimally invasive detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients is a promising tool to select patients for targeted therapy in order to improve their prognosis. This study aimed to identify a sensitive, cost-effective, and easily accessible noninvasive method for detecting the EGFR-targetable mutations in the plasma exosomal DNA (exoDNA)+ of patients with NSCLC.</p><p><strong>Methods: </strong>This retrospective observational study was conducted over 10 months, from December 2022 to October 2023, at Masih Daneshvari Hospital in Tehran, Iran. A total of 30 patients with stage II-IV NSCLC and targetable mutation in the EGFR gene were included in the study. Nested PCR and Sanger sequencing were used to evaluate EGFR mutations in the DNA extracted from circulating exosomes.</p><p><strong>Results: </strong>The study found a sensitivity of 76.6% for EGFR mutation detection on exoDNA compared to tissue results. No significant impact was observed based on tumor staging, histology, mutation type, smoking status, gender, or age.</p><p><strong>Conclusion: </strong>Therapeutically targetable driver mutations in the EGFR gene can be accurately detected using nested PCR followed by direct sequencing of plasma exoDNA from patients with NSCLC. This approach facilitates timely and more personalized treatment for NSCLC patients, ultimately improving patient prognosis. Additionally, this method reduces the reliance on invasive tissue biopsies and their associated complications.</p>","PeriodicalId":14500,"journal":{"name":"Iranian Biomedical Journal","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444484/pdf/","citationCount":"0","resultStr":"{\"title\":\"Assessing the Sensitivity of Nested PCR Followed by Direct Sequencing on Exosomal DNA for EGFR Mutation Detection in NSCL\",\"authors\":\"Mohammad Mehdi Jahani, Parisa Mashayekhi, Mir Davood Omrani, Adnan Khosravi, Dehghanifard Ali, Sanam Azad Manjiri, Mahyar Zahraei, Maryam Mabani, Sharareh Seifi, Babak Salimi, Parsa Rostami\",\"doi\":\"10.61186/ibj.4289\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Early and minimally invasive detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients is a promising tool to select patients for targeted therapy in order to improve their prognosis. This study aimed to identify a sensitive, cost-effective, and easily accessible noninvasive method for detecting the EGFR-targetable mutations in the plasma exosomal DNA (exoDNA)+ of patients with NSCLC.</p><p><strong>Methods: </strong>This retrospective observational study was conducted over 10 months, from December 2022 to October 2023, at Masih Daneshvari Hospital in Tehran, Iran. A total of 30 patients with stage II-IV NSCLC and targetable mutation in the EGFR gene were included in the study. Nested PCR and Sanger sequencing were used to evaluate EGFR mutations in the DNA extracted from circulating exosomes.</p><p><strong>Results: </strong>The study found a sensitivity of 76.6% for EGFR mutation detection on exoDNA compared to tissue results. No significant impact was observed based on tumor staging, histology, mutation type, smoking status, gender, or age.</p><p><strong>Conclusion: </strong>Therapeutically targetable driver mutations in the EGFR gene can be accurately detected using nested PCR followed by direct sequencing of plasma exoDNA from patients with NSCLC. This approach facilitates timely and more personalized treatment for NSCLC patients, ultimately improving patient prognosis. Additionally, this method reduces the reliance on invasive tissue biopsies and their associated complications.</p>\",\"PeriodicalId\":14500,\"journal\":{\"name\":\"Iranian Biomedical Journal\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444484/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Iranian Biomedical Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.61186/ibj.4289\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Biochemistry, Genetics and Molecular Biology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Biomedical Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.61186/ibj.4289","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

摘要

背景:非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)突变的早期微创检测是选择患者进行靶向治疗以改善其预后的有效工具。本研究旨在确定一种灵敏、经济、易行的非侵入性方法,用于检测非小细胞肺癌患者血浆外泌体DNA(exoDNA)+中的表皮生长因子受体(EGFR)靶向突变:这项回顾性观察研究于 2022 年 12 月至 2023 年 10 月在伊朗德黑兰的 Masih Daneshvari 医院进行,历时 10 个月。研究共纳入了 30 名表皮生长因子受体(EGFR)基因可靶向突变的 II-IV 期 NSCLC 患者。研究采用巢式 PCR 和 Sanger 测序法评估从循环外泌体中提取的 DNA 中的表皮生长因子受体突变:研究发现,与组织结果相比,外泌体DNA检测表皮生长因子受体基因突变的灵敏度为76.6%。根据肿瘤分期、组织学、突变类型、吸烟状况、性别或年龄,未观察到明显影响:结论:利用巢式 PCR 对 NSCLC 患者的血浆外 DNA 进行直接测序,可以准确检测出表皮生长因子受体(EGFR)基因中具有治疗靶向性的驱动突变。这种方法有助于对 NSCLC 患者进行及时和更加个性化的治疗,最终改善患者的预后。此外,这种方法还能减少对侵入性组织活检及其相关并发症的依赖。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Assessing the Sensitivity of Nested PCR Followed by Direct Sequencing on Exosomal DNA for EGFR Mutation Detection in NSCL

Background: Early and minimally invasive detection of epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients is a promising tool to select patients for targeted therapy in order to improve their prognosis. This study aimed to identify a sensitive, cost-effective, and easily accessible noninvasive method for detecting the EGFR-targetable mutations in the plasma exosomal DNA (exoDNA)+ of patients with NSCLC.

Methods: This retrospective observational study was conducted over 10 months, from December 2022 to October 2023, at Masih Daneshvari Hospital in Tehran, Iran. A total of 30 patients with stage II-IV NSCLC and targetable mutation in the EGFR gene were included in the study. Nested PCR and Sanger sequencing were used to evaluate EGFR mutations in the DNA extracted from circulating exosomes.

Results: The study found a sensitivity of 76.6% for EGFR mutation detection on exoDNA compared to tissue results. No significant impact was observed based on tumor staging, histology, mutation type, smoking status, gender, or age.

Conclusion: Therapeutically targetable driver mutations in the EGFR gene can be accurately detected using nested PCR followed by direct sequencing of plasma exoDNA from patients with NSCLC. This approach facilitates timely and more personalized treatment for NSCLC patients, ultimately improving patient prognosis. Additionally, this method reduces the reliance on invasive tissue biopsies and their associated complications.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Iranian Biomedical Journal
Iranian Biomedical Journal Biochemistry, Genetics and Molecular Biology-Biochemistry, Genetics and Molecular Biology (all)
CiteScore
3.20
自引率
0.00%
发文量
42
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信